Eaton Vance Management’s Royalty Pharma RPRX Stock Holding History

Eaton Vance Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$47.8M	Sell	1,189,393 -36,612	-3%	-$1.56M	0.07%	271
2022 Q2	$51.5M	Buy	1,226,005 +110,957	+10%	+$4.55M	0.07%	258
2022 Q1	$43.4M	Buy	1,115,048 +106,698	+11%	+$4.19M	0.05%	338
2021 Q4	$40.2M	Buy	1,008,350 +12,482	+1%	+$485K	0.05%	338
2021 Q3	$36.1M	Sell	995,868 -387,205	-28%	-$15M	0.05%	324
2021 Q2	$56.7M	Buy	1,383,073 +374,100	+37%	+$15.9M	0.08%	243
2021 Q1	$44M	Buy	1,008,973 +146,833	+17%	+$6.96M	0.07%	289
2020 Q4	$43.1M	Buy	862,140 +308,143	+56%	+$13.1M	0.07%	266
2020 Q3	$23.3M	Buy	553,997 +112,146	+25%	+$4.81M	0.04%	335
2020 Q2	$21.5M	Buy	+441,851	New	+$21.9M	0.04%	327

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SGA

Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

Eaton Vance Management's RPRX Position: Q3 2022 in Review

Eaton Vance Management reduced its Royalty Pharma (RPRX) stake by 3% in Q3 2022, selling an estimated $1.56M and leaving 1,189,393 shares worth $47.8M. The position accounts for 0.07% of the portfolio, ranked #271.

Eaton Vance Management first reported a position in RPRX in Q2 2020 and has held it in 10 quarters since. The position peaked at $56.7M in Q2 2021. 319 funds tracked by Wall St. Rank hold RPRX as of Q3 2022.

Eaton Vance Management held 1,189,393 shares of Royalty Pharma worth $47.8M as of Q3 2022.
Eaton Vance Management sold 36,612 Royalty Pharma shares in Q3 2022, an estimated $1.56M.
Royalty Pharma made up 0.07% of Eaton Vance Management's portfolio in Q3 2022, its #271 holding.
Eaton Vance Management first reported a position in Royalty Pharma in Q2 2020 and has held it in 10 quarters since.
Eaton Vance Management's Royalty Pharma position peaked at $56.7M in Q2 2021.
319 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2022.

Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.